Impacto clínico y en costes sanitarios de alteraciones de potasio en pacientes con enfermedades cardiovasculares, metabólicas y renales crónicas-Reference-Cited by-同舟云学术

Impacto clínico y en costes sanitarios de alteraciones de potasio en pacientes con enfermedades cardiovasculares, metabólicas y renales crónicas

Published:2021-04 Issue:4 Volume:74 Page:312-320
ISSN:0300-8932
Container-title:Revista Española de Cardiología
language:es
Short-container-title:Revista Española de Cardiología

Author:

Jiménez-Marrero Santiago,Cainzos-Achirica Miguel,Monterde David,Vela Emili,Cleries Montse,García-Eroles Luis,Enjuanes Cristina,Yun Sergi,Garay Alberto,Moliner Pedro,Alcoberro Lidia,Corbella Xavier,Comin-Colet Josep

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference18 articles.

1. Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice;De Nicola;J Nephrol.,2018

2. Potassium homeostasis and pathophysiology of hyperkalaemia;Kjeldsen;Eur Heart J Suppl.,2019

3. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

4. Physiology and Pathophysiology of Potassium Homeostasis: Core Curriculum 2019;Palmer;Am J Kidney Dis.,2019

5. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure;Collins;Chronic Kidney Disease, and/or Diabetes. Am J Nephrol.,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis;European Journal of Internal Medicine;2024-07

2. Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain;Nefrología (English Edition);2023-11

3. Impacto económico del uso de patiromer en enfermedad renal crónica o insuficiencia cardíaca para el tratamiento de la hiperpotasemia crónica en España;Nefrología;2022-09

4. A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain;Journal of Medical Economics;2022-05-19

5. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics;Journal of Clinical Medicine;2022-02-22